Stannsoporfin (INH-001)
Prevention of severe hyperbilirubinemia in newborns
Phase 3Development
Key Facts
Indication
Prevention of severe hyperbilirubinemia in newborns
Phase
Phase 3
Status
Development
Company
About Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals was a global specialty biopharmaceutical company with a complex history, culminating in a strategic breakup. Its mission centered on developing and commercializing therapies for severe conditions in autoimmune, rare diseases, and critical care. Key achievements included the commercialization of products like TERLIVAZ® for HRS-1 and the resolution of significant litigation through bankruptcy. The company's final strategy involved merging with Endo and subsequently separating into two focused companies to unlock value and streamline operations.
View full company profile